VIBRANT is a study to see if a medicine called VIB4920 helps treat lupus nephritis (LN). Lupus nephritis is a kidney problem caused by lupus, a disease where the immune system attacks healthy body parts. Participants will receive either VIB4920 or a placebo (a substance with no active medicine) through an IV (a way to give medicine directly into the blood) over 24 weeks. They will also take other medications: mycophenolate mofetil (MMF) and prednisone, which help reduce the immune system's attack on the kidneys. The main goal is to see if kidney health improves by week 36. The study will last until week 60.

• Participants need to visit the study center frequently for IV treatments and check-ups.
• The study offers medication and regular health monitoring but involves risks common with new treatments.
• Participants must meet specific health criteria and agree to the study's rules.